Remove CMS Remove Exercise Remove Ischemia
article thumbnail

BioCardia’s CardiAMP Cell Therapy Chronic Myocardial Ischemia Trial Results Show Patient Benefits in Important Outcomes

DAIC

a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced the primary endpoint results of the open label roll-in cohort of the CardiAMP Cell Therapy in Chronic Myocardial Ischemia Trial. Getty Images milla1cf Thu, 05/02/2024 - 10:12 May 2, 2024 — BioCardia, Inc. ,

article thumbnail

GE Healthcare Launches New Cardiac PET tracer

DAIC

ii to show blood flow through the heart muscle and evaluate the presence, extent and degree of myocardial ischemia or infarction. Around 6 million MPI procedures are undertaken each year in theU.S. Flyrcado is now available in selectU.S.markets.

article thumbnail

Patients Undergo First Doses of New Cardiac PET tracer

DAIC

Additionally, it offers clinicians the flexibility to perform exercise stress testingsomething not feasible with any previously available cardiac PET tracer. The longer half-life eliminates the need for onsite tracer manufacturing so it can be ordered as a ready-to-use unit dose. National Center for Health Statistics.